Glenn Hanna, MD – Dana-Farber
The combination of BCA101 and pembrolizumab as first-line therapy in patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) shows promising anti-tumor activity, especially in HPV-negative patients, with manageable side effects. These dose expansion results highlight the potential of this combination treatment and support the need for further investigation. The study, funded by Bicara Therapeutics and conducted in collaboration with Merck Sharp & Dohme LLC, demonstrates the clinical potential of BCA101 and pembrolizumab in this patient population (Clinical trial information: NCT04429542).